FDA Requests More Information on Halted Dynavax Technologies Corporation Study

NEW YORK - Shares of Dynavax Technologies Corp. fell Thursday as the biotechnology company responded to a Food and Drug Administration request for more information on a halted study of the developing hepatitis B vaccine Heplisav.